Download the presentation here: PDF
Download the presentation here: PDF
Download the presentation here: PDF
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
NGF Antagonists: A Growing Pipeline<br />
• Including tanezumab, at least 10 compounds (monoclonal antibodies and small<br />
molecules) have been generated to inhibit NGF signaling. Currently only two drugs are<br />
reportedly in clinical trials, Pfizer’s tanezumab and OrthoMcNeil/Janssen<br />
Pharmaceuticals’ AMG 403 (although <strong>the</strong> status is unknown). O<strong>the</strong>r pharma companies<br />
likely have early stage programs.<br />
Drug<br />
Tanezumab<br />
AMG 403<br />
PG110<br />
PPC-1807<br />
VMD-902<br />
BXL1H5<br />
Anti-NGF<br />
ALE 0540<br />
ReN 1820<br />
ReN 1826<br />
???<br />
90<br />
Company<br />
Pfizer<br />
Amgen/OMJP/Takeda<br />
PainCeptor<br />
VM Discovery<br />
BioXell<br />
Yonsei University College<br />
of Medicine<br />
NPS Pharmaceuticals<br />
ReNeuron<br />
ReNeuron<br />
Big Pharma A,B & C<br />
Adis R&D Insight; IDdb3; Company websites<br />
Lay Line<br />
Genomics/PanGenetics<br />
Class<br />
mAB - NGF<br />
mAB/peptibody - NGF<br />
mAB - NGF<br />
Small molecule<br />
Small molecule<br />
mAB – TrkA<br />
mAB - NGF<br />
Small molecule<br />
Soluble TrkA<br />
Modified ReN 1820<br />
mAB - NGF<br />
© Defined Health, 2009<br />
Pain Insight Briefing<br />
Status<br />
Phase II - Pain<br />
Phase I - Pain<br />
PC - Pain<br />
PC - Pain<br />
PC - Pain<br />
PC - Pain<br />
No development<br />
reported(PC)<br />
Discontinued (PC) -<br />
Neuropathic pain<br />
Discontinued (PC) -<br />
Inflammation<br />
Discontinued (PC) - cancer<br />
???